Bioxcel Therapeutics Logo
Previous slide
Next slide

Our AI-based approach is designed to:

Latest News

Oct 15, 2024
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress DisorderVIEW RELEASE
Sep 19, 2024
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for AgitationVIEW RELEASE
Sep 05, 2024
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE

Stock Information

BioXcel Therapeutics, Inc.

Oct 15, 2024 04:00 PM

MARKET/SYMBOL

Nasdaq:

BTAI

PRICE

0.5689

CHANGE

0.0325 (6.06%)
Scroll to Top

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries. This web site is intended to help healthcare professionals practicing in the US find scientifically balanced, evidence-based information about Bioxcel Therapeutics drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.